Akari Therapeutics PLC AKTX
$7.85 $0.06 (0.77%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
AKTX Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Akari Therapeutics PLC is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Akari Therapeutics PLC. Stock Analysis AKTX
United States Health Care Nano Cap Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in Tampa, Florida and currently employs 5 full-time employees. The company went IPO on 2014-01-31. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. The company is pursuing research on two additional novel payloads, such as PH5 and PH6. The company also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
Akari Therapeutics PLC (AKTX) Chart
Financial Metrics & Statements of Akari Therapeutics PLC (AKTX)
FAQ's for Akari Therapeutics PLC (AKTX)
- As of August 2026, Akari Therapeutics PLC AKTX is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Akari Therapeutics PLC using these criteria to determine its compliance status.
- Muslim investors may consider investing in Akari Therapeutics PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Akari Therapeutics PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Akari Therapeutics PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Akari Therapeutics PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Akari Therapeutics PLC (AKTX)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
